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Hypertension awareness and treatment improved in the 
United States over the last 2 decades, contributing to a nearly 
50% improvement in the proportion of hypertensive patients 
with controlled blood pressure (BP).1 Hypertension treat-
ment, control, and awareness improved in non-Hispanic 
blacks, but hypertension prevalence and the proportion of 
uncontrolled BP in non-Hispanic black hypertensive patients 
remain higher compared with non-Hispanic whites. Rates of 
deaths attributable to hypertension have increased over time 
in non-Hispanic black men, in whom mortality rates are dou-
ble that of non-Hispanic white men.2 Hypertension awareness 
and treatment also continue to be lowest in young adults,1 and 
hypertension screening and control have been especially dif-
ficult to implement in young non-Hispanic black men.3,4
Our recent cost-effectiveness modeling study found that 
implementing 2014 US hypertension guidelines would be 
cost saving overall in untreated hypertensive adults aged 
35–74 years old, but cost-effectiveness did not extend to pri-
mary of 35- to 44-year-old women with stage 1 hyperten-
sion for primary cardiovascular disease (CVD) prevention.5 
Given their higher CVD risk, we hypothesized that hyper-
tension treatment would be more cost-effective in young 
and middle-aged non-Hispanic blacks compared with same-
aged non-Hispanic whites. We therefore compared the cost-
effectiveness of implementing 2014 hypertension guidelines 
in untreated non-Hispanic black and non-Hispanic white 
patients overall and by age, sex, hypertension stage, and 
CVD, diabetes, and chronic kidney disease (CKD) status.
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BACKGROUND
We compared the cost-effectiveness of hypertension treatment in non-
Hispanic blacks and non-Hispanic whites according to 2014 US hyper-
tension treatment guidelines.
METHODS
The cardiovascular disease (CVD) policy model simulated CVD events, 
quality-adjusted life years (QALYs), and treatment costs in 35- to 74-year-
old adults with untreated hypertension. CVD incidence, mortality, and 
risk factor levels were obtained from cohort studies, hospital registries, 
vital statistics, and national surveys. Stage 1 hypertension was defined 
as blood pressure 140–149/90–99 mm Hg; stage 2 hypertension as 
≥150/100 mm Hg. Probabilistic input distribution sampling informed 
95% uncertainty intervals (UIs). Incremental cost-effectiveness ratios 
(ICERs) < $50,000/QALY gained were considered cost-effective.
RESULTS
Treating 0.7 million hypertensive non-Hispanic black adults would 
prevent about 8,000 CVD events annually; treating 3.4 million 
non-Hispanic whites would prevent about 35,000 events. Overall 
2014 guideline implementation would be cost saving in both 
groups compared with no treatment. For stage 1 hypertension but 
without diabetes or chronic kidney disease, cost savings extended 
to non-Hispanic black males ages 35–44 but not same-aged 
non-Hispanic white males (ICER $57,000/QALY; 95% UI $15,000–
$100,000) and cost-effectiveness extended to non-Hispanic black 
females ages 35–44 (ICER $46,000/QALY; $17,000–$76,000) but 
not same-aged non-Hispanic white females (ICER $181,000/QALY; 
$111,000–$235,000).
CONCLUSIONS
Compared with non-Hispanic whites, cost-effectiveness of implement-
ing hypertension guidelines would extend to a larger proportion of 
non-Hispanic black hypertensive patients.
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The CVD policy model is a computer-simulation, state-
transition model of incidence, prevalence, mortality, and 
costs of CVD in the United States (Supplementary Figure). 
The primary study population included non-Hispanic 
black and white men and women aged 35–74 in 2014 who 
were not receiving pharmacotherapy for hypertension. We 
restricted our analysis to currently untreated hypertensive 
patients because we were not able to discern among differ-
ent causes of uncontrolled BP in already treated patients 
(financial obstacles, nonadherence, side effects, or contrain-
dications due to comorbidities). Adults aged 75  years and 
older were excluded from this analysis due to highly variable 
rates of medication-related adverse events.6 We were unable 
to analyze Hispanic Americans or Asian Americans at this 
time due to insufficient contemporary CVD incidence data 
for these heterogeneous groups.
Means or proportions and joint distributions of risk fac-
tors, including systolic and diastolic BP, cholesterols, and 
hypertension medication use, smoking, diabetes, and CKD 
status, were estimated from pooled National Health and 
Nutrition Examination Surveys (NHANES) 2007–2010 by 
10-year age categories, sex, and race/ethnic group. NHANES 
2007–2010 systolic BP was categorized into 3 main catego-
ries: <140, 140–159 (stage 1 hypertension), and ≥160 mm Hg 
(stage 2 hypertension). To assess 2014 guideline treatment 
recommendations in older adults (ages 60–74 years), stage 
1 systolic BP was further divided into the intervals 140–149 
and 150–159 mm Hg. Diastolic BP categories were <90, 
90–99 (stage 1), and ≥100 mm Hg (stage 2). Hypertensive 
patients were considered untreated if they answered no 
to both NHANES questions: “Because of your high blood 
pressure/hypertension, have you ever been told to take pre-
scribed medicine?” and “Are you currently taking medica-
tion to lower your blood pressure?”
Default multivariate stroke and coronary heart dis-
ease incidence functions were estimated in an original 
Framingham Heart Study analysis. The CVD policy model 
simulated CVD events, non-CVD deaths, quality-adjusted 
life years (QALYs), and hypertension and CVD treatment 
costs of implementing 2014 US treatment guidelines in 
untreated hypertensive non-Hispanic black and white adults 
aged 35–74 years compared with no treatment.
Race/ethnic-specific CVD policy models
While the structure of both the non-Hispanic black and 
non-Hispanic white CVD policy model versions is identical 
to that of the national model, several inputs were re-pop-
ulated with data specific to non-Hispanic blacks and non-
Hispanic whites (for details, see Supplementary Text).
Population projections for the years 2014–2024 were 
obtained from 2010 US Census Bureau. National Health 
Interview Survey data were used to estimate the proportion 
of adults with known coronary heart disease, stroke, or both 
these conditions. All beta coefficients for the effect of non-BP 
risk factors on incident stroke (diabetes, CKD, and smoking) 
and on incident coronary heart disease (cholesterols, diabe-
tes, CKD, and smoking) were estimated from Framingham 
Heart Study data. Numbers of 2010 CVD deaths (stroke 
(ICD-10 codes I60–I69), coronary heart disease (I20–I25 
and two-thirds of I49, I50, and I51), and hypertensive heart 
disease deaths (I11.0, I11.9)) and non-CVD deaths (remain-
der of ICD codes) reported by the Centers for Disease 
Control (CDC WONDER) for 2010 were used as model cali-
bration targets.
Hospitalized stroke incidence in non-Hispanic whites 
was based on rates observed in the 2010 National Hospital 
Discharge Survey (NHDS). Since NHDS is missing over 
15% of data on self-reported race/ethnicity, we were unable 
to similarly determine the number of total stroke events in 
non-Hispanic blacks. For non-Hispanic black stroke inci-
dence rates, we first adjusted national NHDS-based stroke 
incidence rates for risk factor differences between the United 
States and racial subpopulations and the stronger associa-
tion between BP and stroke in non-Hispanic blacks.7 Stroke 
incidence rate inputs for both groups were calibrated until 
simulated stroke deaths predicted 2010 national stroke mor-
tality numbers within 1% (Supplementary Table  1). The 
resulting incidence of hospitalized stroke approximated age- 
and sex-specific stroke incidence rates observed in stroke 
cohorts and surveillance studies of non-Hispanic blacks and 
whites.8–13
Non-Hispanic white age-range/gender-specific coronary 
heart disease incidence rates were estimated by calibrating 
incidence to match with cause-specific coronary heart disease 
mortality in 2010. Coronary heart disease incidence for non-
Hispanic blacks was estimated by multiplying white age and 
sex incidence rates by black/white incidence ratios observed 
during the 2005–2011 interval in the Atherosclerosis Risk 
in Communities (ARIC) surveillance study. Coronary heart 
disease incidence rate inputs for both groups were calibrated 
until simulated coronary heart disease deaths predicted 
2010 national mortality numbers within 1% (Supplementary 
Table 1).
Thirty-day acute myocardial infarction case fatality was 
assumed to be similar for non-Hispanic blacks and whites 
in 2010.14 Stroke 30-day case fatality rates for non-Hispanic 
blacks were assumed to be higher than national averages 
based on an observed difference between white and black 
case fatality rates in the ARIC cohort study.8 Annual proba-
bilities of stroke after myocardial infarction15 and the proba-
bility of coronary heart disease in stroke patients were based 
on natural history studies and were assumed to be the same 
for both race/ethnic groups (Supplementary Text). Deaths, 
disability, and costs of heart failure due to coronary heart 
disease were tabulated by the CVD policy model. Deaths 
attributable to heart failure due to hypertensive heart dis-
ease (and not due to coronary heart disease) were tabulated, 
but chronic costs and nonfatal disability due to hypertensive 
heart disease were not.
Hypertension treatment model inputs
The 2014 US hypertension guidelines (“JNC 8”) recom-
mended a goal of <140/90 mm Hg for diabetes and/or CKD, 
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age > 60 years without diabetes or CKD.16 The number of US 
non-Hispanic black and white adults eligible for treatment 
under JNC 8 was estimated using these categories and BP 
and treatment status information in NHANES 2007–2010.
BP change due to antihypertensive medications was 
determined by pretreatment BP and the number of standard 
doses of medications needed to reach the guideline BP goal, 
according to a trials-based formula.17 BP changes were cal-
culated based on pretreatment BP, age, and sex. We assumed 
the same BP reduction per standard dose of the main drug 
classes (Table  1; Supplementary Text).17,18 Quality of life 
penalties were applied for side effects.17 Treatment costs 
included hypertension monitoring costs, drug side effects, 
and the average wholesale cost of drugs. We assumed the 
75% adherence observed in the same clinical trials meta-
analysis that provided the association between BP reduc-
tion and CVD risk reduction.18 In our prior analysis, lower 
adherence reduced effectiveness and costs proportionally; 
thus, lower adherence reduced population impact but had 
little effect on cost-effectiveness.5
We assumed CVD risk reduction is due to BP reduction,18 
and that BP is lowered to a similar extent across classes when 
comparing per-class standard doses.17,27 We started with 
observational Prospective Studies Collaboration age-specific 
relative risks and 95% confidence intervals for coronary 
heart disease and stroke per 10 mm Hg change in systolic 
BP or 5 mm Hg diastolic BP (Table 1).28 Age-specific rela-
tive risk inputs were calibrated to be within ≤0.02 of these 
estimates and overall relative risks within 95% confidence 
interval bounds of the summary estimate from a large meta-
analysis of randomized clinical trials of hypertension treat-
ment (Supplementary Tables 2 and 3).18 The stroke relative 
risk estimate was found to be close to the pooled estimate 
from the East Asian trials included in that analysis (0.59 
(0.49–0.71); Supplementary Text). The resulting relative 
risk assumptions were validated for treatment of systolic 
BP in ages 60–74  years by simulating the treatment and 
placebo groups of the Systolic Hypertension in the Elderly 
Program (SHEP) trial and comparing simulated relative rate 
ratios with those observed in the trial (Supplementary Text; 
Supplementary Table 4).
Main analysis
A status quo simulation projected CVD events, CVD 
deaths, and heart failure deaths, costs, and QALYs for non-
Hispanic black and white adults aged 35–74  years with 
untreated hypertension from 2014 to 2024. We then simu-
lated CVD outcomes treating to JNC 8 BP targets in non-
Hispanic blacks and whites with subgroup analysis stratified 
by age groups (under and over 60 years) and status of CVD, 
CKD, or diabetes. Incremental cost-effectiveness ratios 
(ICERs) were calculated as change in costs divided by incre-
mental change in QALYs. ICERs < $50,000/QALY gained 
were considered cost-effective, ≥$50,000 and <$150,000 of 
intermediate value, and ≥$150,000 of low value.29 All analy-
ses were approached from a payer’s perspective. Future costs 
and QALYs were discounted at 3% per year. ICERs compared 
costs and costs savings associated with treating patients to 
JNC 8 guidelines vs. no treatment within age groups and by 
CVD, diabetes, and CKD status.
In an exploratory analysis, we simulated alternative sce-
narios applying nonpharmacologic diet and exercise (life-
style) interventions alone to lower BP in stage 1 hypertension 
without diabetes or CKD based on the upper and lower 95% 
confidence interval bounds of a summary effectiveness esti-
mate from lifestyle intervention trials.30 Reduction in total 
cardiovascular events due to lifestyle interventions was esti-
mated, but cost analysis for lifestyle intervention was not 
done due to poor and inconsistent data available on the cost 
of these interventions.
Multivariate, probabilistic sensitivity analysis
We did not perform 1-way sensitivity analyses since 
uncertainties surrounding each model input were explored 
extensively in our prior analysis.5 Uncertainty distributions 
of the main inputs, including clinical effectiveness of BP low-
ering, relative risk of CVD associated with BP change, qual-
ity of life decrements due to side effects, and costs related 
to side effects, medications, and monitoring, were randomly 
sampled 1,000 times in probabilistic simulations. From these 
results, we calculated 95% uncertainty intervals (UIs) for all 
model outputs.
RESULTS
About 130,000 non-Hispanic blacks and 570,000 non-His-
panic whites with CVD and hypertension but not currently 
treated with medications would be eligible for secondary 
prevention every year during the 2014–2024. Treating these 
patients was estimated to prevent about 2,000 and 10,000 
CVD events in black and white populations, respectively 
(Table  2). Additionally, 1.7 million non-Hispanic blacks 
and 5.4 million non-Hispanic whites aged 35–74 years with 
hypertension were eligible for primary prevention treat-
ment. Treating these patients to 2014 guideline targets was 
projected to prevent about 6,000 and 25,000 CVD events in 
non-Hispanic black and non-Hispanic white populations, 
respectively (Table 2).
Hypertension treatment was cost saving overall in both 
non-Hispanic blacks and non-Hispanic whites compared 
with no treatment (Table 2). Incremental addition of treat-
ment of stage 1 hypertension for primary prevention to 
treatment of CVD and stage 2 patients was also cost-effective 
in both groups overall.
When treatment was assessed in progressively less cost-
effective strategies, cost savings were observed in a greater 
proportion of subgroups in the non-Hispanic black popu-
lation compared with the non-Hispanic white adults. In 
non-Hispanic blacks, treating hypertension for primary pre-
vention in males of all ages and BP stages was cost saving, 
regardless of diabetes or CKD status (Figure 1). Treatment 
was also cost saving in all non-Hispanic black women with 
stage 2 hypertension and in those aged 45–74  years with 
stage 1 hypertension. Treating non-Hispanic black women 
aged 35–44 years with stage 1 hypertension was cost-effec-
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Table 1. Main assumptions and uncertainty ranges used for the comparative effectiveness analysis of US BP treatment guidelines
Variable
Estimate (range in upper and lower bound estimates  
if a variation assumed according to age and/or sex)
SourcesMain Lower Upper
Effectiveness
 Average RR per 5 mm Hg reduction in diastolic BP or 10 mm Hg reduction in systolic BP, ages 35–59 yearsa
  CHD 0.73 (0.72–0.74) 0.70 (0.67–0.72) 0.77 (0.76–0.78) Law, Morris, and Wald meta-analysis18
  Stroke 0.64 (0.61–0.66) 0.59 (0.54–0.63) 0.69 (0.68–0.69)
  All-cause mortality 0.86 (0.83–0.89) 0.76 0.95
 Average RR per 10 mm Hg reduction in systolic BP or 5 mm Hg reduction in diastolic BP, ages 60–74 yearsa
  CHD 0.77 (0.74–0.78) 0.74 (0.72–0.76) 0.79 (0.76–0.81) Law, Morris, and Wald meta-analysis,18 
Systolic Hypertension in the Elderly 
Program (SHEP) all-cause mortality 
upper bound 95% interval for upper 
estimate19
  Stroke 0.69 (0.66–0.71) 0.64 (0.62–0.64) 0.74 (0.69–0.78)
  All-cause mortality 0.91 (0.91–0.92) 0.80 1.02
 Average systolic BP-lowering effect (mm Hg)b
  Stage 2 hypertension
    Age <60 years, pretreatment ≥ 
160 mm Hg target 140 mm Hg, 
3–4 standard dose medications
31.0–34.7 26.0–29.4 36.0–39.9 Law, Morris, and Wald meta-analysis18
    Age ≥60 years, pretreatment ≥ 
160 mm Hg target 150 mm Hg, 
2–3 standard dose medications
22.1–24.2 18.1–18.9 27.2–29.2
  Stage 1 hypertension
    Age <60 years, pretreatment 
140–159 mm Hg target 140 mm 
Hg, 0.5–2.0 standard dose 
medications
7.9–10.9 5.9–8.3 9.9–13.4
    Age ≥60 years, pretreatment  
150–159 mm Hg target 150 mm  
Hg, 0.5 standard dose medications
7.1 3.2 11.0
 Diastolic BP-lowering effect (mm Hg)b
   All ages, stage 2  
hypertension (≥100 mm Hg)
17.1 12.0 22.2 Law, Morris, and Wald meta- analysis18
    All ages (target 90 mm Hg, 3 
standard dose medications
   All ages, stage 1 hypertension 
(90–99 mm Hg)
5.3 3.7 6.9
    All ages (target 90 mm Hg,  
1 standard dose medication
 Annual costs per person treated (2010 costs; inflated to 2014 costs in all results)
  Physician office visit
   Treatment monitoring visits (number)
    Stage 2 hypertension 4 3 5 ALLHAT trial (Heidenreich et al.),31 JNC 
7 recommendation. Outpatient visit, 
Medicare Physician Fee Schedule 
(code 99213, nonfacility limiting 
charge)20
    Stage 1 hypertension 3 2 4
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Variable
Estimate (range in upper and lower bound estimates  
if a variation assumed according to age and/or sex)
SourcesMain Lower Upper
    Average cost (used for  
infrequent hospitalized  
drug-related adverse events)
$12,000 Not modeled Not modeled National Inpatient Sample survey
    High cost (used for rare 
hospitalized drug-related  
adverse events)
$21,000
  Laboratory test (electrolytes monitoring on treatment)
   Number of tests 1 1 2 U.S. Joint National Committee 7 
recommendation Centers for Medicare 
and Medicaid laboratory fee schedule
   Cost per test $15 Not modeled Not modeled
  Antihypertensive drug costs (total daily doses)c
   0.5 standard dose $124 Not modeled $296 Average wholesale prices reported by 
manufacturers (“Red Book”; 2010),21 
see Methods text for estimation 
method
   1.0 standard dose $166 $363
   1.5 standard doses $215 $409
   2.0 standard doses $238 $567
   3.0 standard doses $357 $850
   3.5 standard doses $430 $1,311
   4.0 standard doses $496 $1,374
   Pharmacy dispensing feesd $27 $33
  Acute and chronic CVD treatment costs
   Myocardial infarction hospitalization
    Nonfatal $33,000 California Office of Statewide Health 
Planning and Development (OSHPD) 
hospital data, 200822
    Fatal $46,000
    Coronary revascularization procedures
     Percutaneous coronary 
intervention
$21,000–$23,000
     Coronary artery bypass graft 
surgery
$57,000–$59,000
   Stroke
    Fatal $21,000–$26,000
    Nonfatal $15,000–$21,000
   Chronic CHD costs
    First year $11,000 US Medical Expenditure Panel  
Surveys (MEPS), 1998–2008
    Subsequent years $2,000
   Chronic post-stroke costs
    First year $16,000
    Subsequent years $5,000
  Inflation from 2010 to 2014 costs 9% 11% Main = change in general US  
consumer price index; upper =  
change in medical component
Serious adverse effects of medications (incidence per 100,000 person-years)
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Variable
Estimate (range in upper and lower bound estimates  
if a variation assumed according to age and/or sex)
SourcesMain Lower Upper
   3 standard doses 10,039.20 6,950.21 12,742.06 Based on Law 200317
   2 standard doses 7,572.41 5,242.43 9,611.13
   1 standard dose 5,200.00 3,600.06 6,600.00
   0.5 standard dose 2,600.00 1,800.00 3,300.00
  Infrequent, hospitalized
   3 standard doses 193.06 19.31 965.31 Trials, medication labels, post- 
marketing reports
   2 standard doses 145.62 14.56 728.12
   1 standard dose 100.00 10.00 500.00
   0.5 standard dose 50.00 5.00 250.00
  Rare, hospitalized/severe
   3 standard doses 1.93 0.0193 19.31
   2 standard doses 1.46 0.0146 14.56
   1 standard dose 1.00 0.0100 10.00
   0.5 standard dose 0.50 0.0050 5.00
  Death
   3 standard doses 0.0193 0.0002 0.1931
   2 standard doses 0.0146 0.0001 0.1456
   1 standard dose 0.0100 0.0001 0.1000
   0.5 standard dose 0.0050 0.0001 0.0500
Utility (QALY weight penalty, duration)
 Drug side effects managed as 
outpatient (1 day)
0.23 Montgomery23
 Drug side effect requiring 
hospitalization (1 day)
0.50 Clinical judgment
 Acute stroke (1 month) 0.86 Global Burden of Disease 2010 Study24
 Chronic stroke survivors (12 months) 0.85–0.88
 Acute myocardial infarction (1 month) 0.91
 Acute unstable angina (1 month) 0.95
 Chronic CHD (12 months) 0.91–0.98
 Death 1.00
 Disutility due to taking daily 
medications
0.00 0.01–0.02 Past cost-effectiveness analyses20,25,26
Adherence to medications (percent 
of patients continuing prescribed 
treatment)




Not modeled Law, Morris, and Wald meta-analysis  
for main estimate18
Annual discount rate  3% Not modeled Not modeled Assumed
Abbreviations: BP = blood pressure; CHD = coronary heart disease; CVD = cardiovascular disease; QALY = quality-adjusted life year.
aRelative risk reductions vary by age and sex category, see Methods and Supplementary Appendix for details.
bChange in BP dependent on age- and sex-specific distribution of baseline BPs within stage 1 or stage 2 category and number of standard 
dose antihypertensive medications.
cStandard dose medications used to estimate costs: captopril 25 mg twice daily, nifedipine 30 mg daily, amlodipine 5 mg daily, hydrochlo-
rothiazide 25 mg daily, and atenolol 50 mg daily. Combination medications equivalent to two-half standard doses were amlodipine/benazepril 
2.5/10 mg daily and captopril/hydrochlorothiazide 25/25 mg daily. Combination medications equivalent to 1.5 standard doses were captopril/
hydrochlorothiazide 25/25 mg once daily, benazepril/amlodipine 10/2.5 mg daily, or hydrochlorothiazide/propranolol 25/80 mg daily. Combination 
medications equivalent to 2 standard doses were atenolol/chlorthalidone 50/25 mg daily and captopril/hydrochlorothiazide 50/25 mg daily. Of the 
medications listed, only captopril (angiotensin converting enzyme inhibitor) taken divided doses (25 mg twice daily).
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95% UI $3,000–$43,000) and in those without diabetes or 
CKD ($46,000/QALY; 95% UI $17,000–$76,000).
Treating hypertension was cost saving in all non-His-
panic white men with stage 2 hypertension and those aged 
45–74 years with stage 1 hypertension. Treatment was cost-
effective in non-Hispanic white males aged 35–44 years with 
stage 1 hypertension and diabetes or CKD with an ICER 
of about $5,000/QALY gained (95% UI from cost saving to 
$30,000), but of only intermediate value in those with stage 
1 hypertension but without diabetes or CKD (ICER of about 
$57,000/QALY; 95% UI $15,000–$100,000). In non-His-
panic white females, hypertension treatment was only cost 
saving in those 45–74 years old and with stage 2 hyperten-
sion. Treating non-Hispanic white women aged 35–44 years 
with stage 2 hypertension or those aged 45–74  years with 
stage 1 hypertension was cost-effective (Figure 1). Treating 
hypertension in white women aged 35–44 years with stage 
1 hypertension was of intermediate or low value (ICERS ≥ 
$50,000/QALY; 95% UI $46,000–$121,000 with diabetes or 
CKD, $111,000–$235,000 without diabetes or CKD).
For non-Hispanic whites with stage 1 hypertension but 
without diabetes or CKD, lifestyle interventions alone would 
result in about 1,000–3,000 CVD events avoided per year, 
less than the approximately 5,000 events prevented by phar-
macologic treatment alone in the same patients according 
to JNC 8.  For non-Hispanic blacks, lifestyle intervention 
alone in stage 1 patients without diabetes or CKD would 
prevent <1,000 CVD events (about 300–700 fewer), less than 
the approximately 1,000 events that would be prevented by 
pharmacologic treatment alone.
DISCUSSION
Implementation of 2014 hypertension treatment guide-
line goals would reduce CVD morbidity and mortality while 
saving costs overall in both Non-Hispanic whites and blacks 
with untreated hypertension. Compared with non-His-
panic whites, cost savings and cost-effectiveness extended 
to younger ages in non-Hispanic black patients with stage 
1 hypertension. In the short term, implementing guideline 
goals would be cost-effective in 35- to 44-year-old non-His-
panic black females with stage 1 hypertension, but appeared 
to be of intermediate or low value in non-Hispanic white 
females of the same age and hypertension stage.
Over 41% of non-Hispanic blacks aged ≥18  years have 
hypertension, more than 10 percentage points higher than 
other US race/ethnic groups.32 Awareness and treatment have 
improved in all US adults in the past 2 decades,1 but even 
now only about a half of non-Hispanic whites have controlled 
hypertension (50.3%), and the proportion controlled is almost 
9 percentage points lower in non-Hispanic blacks (41.4%).33 
Uncontrolled hypertension is a leading cause of death and 
Figure 1. Incremental cost-effectiveness of implementing JNC 8 hypertension treatment guidelines in previously untreated non-Hispanic black (NHB) 
and non-Hispanic white (NHW) adults with hypertension aged 35–74 years, by age, sex, hypertension stage, and status of diabetes or chronic kidney 
disease (CKD). Within age and sex row, each group is compared with the higher risk group to its left; stage 2 hypertension is compared with patients liv-
ing with cardiovascular disease (CVD) and hypertension. Average annual results from a years 2014–2024 simulation, the CVD policy model. Abbreviation: 











American Journal of Hypertension 9
Value of Hypertension Treatment in US Blacks and Whites
disability in the non-Hispanic black population, and non-
Hispanic black men have the highest rates of hypertension-
related death (hypertensive heart disease, other heart diseases, 
and stroke) of any race/ethnic group.3 Hypertension treat-
ment and control in non-Hispanic black adults is therefore an 
urgent national public health priority. Our results suggest that 
implementing hypertension treatment guidelines in younger 
non-Hispanic black adults is a high-value strategy for health 
system payers, yielding cost savings in older and higher risk 
patients, and cost-effectiveness in younger patients.
Clinical practice-based studies have demonstrated that 
intensive focus on hypertension treatment can lead to remark-
able improvements in BP control.34 Investment in a team-
based approach—supplementing usual care with intensive 
interactions between patient and a nonphysician health care 
provider—may achieve substantial gains.35 Non-Hispanic 
black men aged 21–54 years old in inner-city Baltimore who 
received educational-behavioral-pharmacologic intervention 
from a team including a nurse practitioner and community 
health worker had a >10% higher proportion of controlled 
hypertension after a 36-month intervention, compared with 
those receiving usual care.36 A systematic clinic-based quality 
improvement intervention in the 15 Veteran’s Administration 
medical centers achieved a >30% point improvement in 
hypertension control over 10  years, with similar improve-
ments in non-Hispanic black and white patients.37 A  mul-
ticomponent intervention combining patient education, 
home BP monitoring, and lifestyle counseling in low-income 
non-Hispanic black patients (72% female) did not improve 
hypertension control compared with usual care—in part 
perhaps because the complexity of the intervention led to 
<50% adherence to component interventions.38 The results of 
the SPRINT trial add to decades of evidence demonstrating 
that BP-lowering therapies save lives.18,39 Further research is 
needed on the most effective ways to deliver this highly effec-
tive and cost-effective therapy to all patients seen in clinical 
practice, including non-Hispanic black patients. Lifestyle 
interventions alone in stage 1 patients without diabetes or 
CKD would prevent a more modest number of CVD events 
compared with pharmacologic therapy alone; however, life-
style measures are likely to augment prevention benefits 
when combined with pharmacologic treatment or serve as an 
alternative for patients who decline to take medications.
Due in part to documented barriers to accessing and 
accepting treatment, a significant proportion of non-His-
panic black patients do not regularly seek hypertension and 
other preventive care in medical clinics.3 Recent initiatives 
have tested the strategy of diagnosing and initiating treat-
ment in non-Hispanic black adults outside of the clinic and 
in other community settings, including barbershops, com-
munity centers, and faith-based organizations.3 In the inter-
vention arm of a trial in Dallas, barbers in 17 black-owned 
barbershops were trained to offer BP checks, deliver health 
education, and refer hypertensive patients to medical care.40 
After 10  months, hypertension control was 8.8 percentage 
points higher in the intervention, compared with the usual 
care arm. The Georgia Stroke and Heart Attack Prevention 
Program (SHAPP) is a statewide initiative focused on hyper-
tension screening and control in 16 predominantly rural 
public health districts that are about 56% non-Hispanic 
black. Through provider training, affordable medications, 
adherence support, and community partnerships,41 SHAPP 
achieved approximately 60% hypertension control and was 
projected to save costs compared with no treatment.42 Our 
analysis provides further evidence supporting the value of 
investing in both clinic- and community-based interven-
tions to improve hypertension control in non-Hispanic 
blacks and other high-risk groups with high hypertension 
prevalence.
The methods and reporting of this study conform to 
Consolidated Health Economic Evaluation Reporting 
Standards (CHEERS; see checklist in the Supplementary 
Text),43 and Quality of Health Economic Studies Instrument 
standards recommended for cost-effectiveness analyses of 
US CVD risk factor guidelines.29 Effectiveness assumptions 
were grounded in a large meta-analysis of randomized anti-
hypertensive medication treatment trials and inputs for non-
Hispanic whites and blacks were estimated from national 
data. However, like all computer-simulation analyses, this 
analysis was limited by reliance on multiple assumptions and 
inputs derived from multiple data sources and study types. 
Because of our conservative approach, we did not fully cap-
ture disability and health care costs attributed to hyperten-
sive heart disease or end-stage renal disease—both of which 
are more common in non-Hispanic blacks—so that we may 
have underestimated cost savings and QALY gains with 
hypertension treatment compared with no treatment and in 
between-group comparisons. Additionally, while the 2014 
national guidelines recommended different first-line agents 
for hypertension control in non-Hispanic blacks (diuretics 
or calcium channel blockers) and whites (the same agents 
or renin-angiotensin system blockers),16 the BP response to 
different agents is similar in most patients,44 and we chose 
not to model differential use of antihypertensive medica-
tion classes in order not to bias cost-of-treatment inputs. 
Our projections of future CVD incorporated demographic 
trends but did not account for any secular or clinical practice 
changes in the next decade. Our analysis is further limited by 
its exclusion of other race/ethnic groups, including Hispanic 
Americans and Asian Americans due to the lack of high-
quality data on stroke and coronary heart disease incidence 
in these groups. Further research is needed to elucidate 
hypertension treatment cost-effectiveness in these groups as 
higher quality data becomes available.
Hypertension treatment cost savings and cost-effective-
ness extend to younger ages among non-Hispanic black, 
compared with non-Hispanic white patients. Given their 
the higher hypertension prevalence and heavier burden 
of hypertension-related disease compared with any other 
US race/ethnic group, investment in effective clinic- and 
community-based hypertension control programs in non-
Hispanic black Americans is a particularly high-value 
investment in population health.
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